Based on the rate of smartphone use, iSonea reckons their initial potential market in Australia is 690,000 people, and 4.5 million people in the US. The company says its market research indicates that 80% of GPs and 62% of paediatricians would recommend AirSonea to all patient groups.
The usual caveats apply. iSonea only generated $75,562 in revenue in FY13, and after expensing all research and development costs made a net loss of $5.58 million. But the products it is launching look to have the potential to make a mockery of those numbers.
ISN Price at posting:
77.0¢ Sentiment: Hold Disclosure: Held
